Alex Goldberg

Celgene Corporation (NASDAQ:CELG) and American Capital Agency Corp. (NASDAQ:AGNC) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/24/2014 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Celgene Corporation (NASDAQ:CELG) and American Capital Agency Corp. (NASDAQ:AGNC).

Celgene Corporation (NASDAQ:CELG) a biopharmaceutical company that discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally closed down in its previous session (-1.60%) on 3,560,263 shares traded. Celgene Corporation (NASDAQ:CELG) is currently down (-8.26%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Celgene Corporation (NASDAQ:CELG)

American Capital Agency Corp. (NASDAQ:AGNC) a company that operates as a real estate investment trust closed down in its previous session (-0.63%) on 5,731,103 shares traded. American Capital Agency Corp. (NASDAQ:AGNC) is currently down (-34.16%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about American Capital Agency Corp. (NASDAQ:AGNC)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com